Literature DB >> 1728869

Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin.

S I Rapaport1, A Zivelin, R A Minow, C S Hunter, K Donnelly.   

Abstract

Two patients exposed during surgery to bovine thrombin developed antibodies reacting with both bovine and human thrombin and Factor V. Their thrombin times were markedly prolonged with bovine thrombin and modestly prolonged with human thrombin. High titer anti-bovine Factor V created diagnostic confusion in one patient by neutralizing bovine Factor V in a prothrombin assay substrate. Although weaker, antibody activity against human Factor V led to postoperative factor V deficiency in both patients. Such cross-reacting antibodies, recognizable by their higher titer against bovine than human Factor V, should be suspected when a patient surgically exposed to bovine thrombin develops a Factor V anticoagulant after operation. Crossed immunoelectrophoresis of adsorbed bovine plasma with each patient's plasma as antibody revealed many precipitin arcs indicative of immunization of the patients to additional proteins in a commercial thrombin preparation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1728869     DOI: 10.1093/ajcp/97.1.84

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

1.  Immunological consequences of topical bovine thrombin.

Authors:  J L Zehnder; L L Leung
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.

Authors:  J G Schoenecker; R K Hauck; M C Mercer; W Parker; J H Lawson
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

3.  Exposure of mice to topical bovine thrombin induces systemic autoimmunity.

Authors:  J G Schoenecker; R K Johnson; A P Lesher; J D Day; S D Love; M R Hoffman; T L Ortel; W Parker; J H Lawson
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.

Authors:  T L Ortel; M C Mercer; E H Thames; K D Moore; J H Lawson
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

Review 5.  The past, present, and future of enzyme-based therapies.

Authors:  Jennifer N Hennigan; Michael D Lynch
Journal:  Drug Discov Today       Date:  2021-09-16       Impact factor: 7.851

6.  Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

Authors:  T L Ortel; M A Quinn-Allen; L A Charles; D Devore-Carter; W H Kane
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

7.  Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.

Authors:  B Tribl; P Knöbl; K Derfler; S Kapiotis; G Aspöck; U Jäger; W Hörl; K Lechner
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

8.  Severe postoperative hemorrhage caused by antibody-mediated coagulation factor deficiencies: report of two cases.

Authors:  Tomoya Miura; Daisuke Ban; Takatoshi Koyama; Atsushi Kudo; Takanori Ochiai; Takumi Irie; Noriaki Nakamura; Shinji Tanaka; Shigeki Arii
Journal:  Surg Today       Date:  2013-05-23       Impact factor: 2.549

9.  Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.

Authors:  Paul Ness; Michael Creer; George M Rodgers; Joseph J Naoum; Kenneth Renkens; Stacy A Voils; W Allan Alexander
Journal:  Patient Saf Surg       Date:  2009-05-22

10.  Clinical use of topical thrombin as a surgical hemostat.

Authors:  Wesley K Lew; Fred A Weaver
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.